O35 Photodynamic therapy and combined treatment modalities in head and neck cancer patients with Radaclorin

Currently, data regarding optimal treatment modality, response, and outcome specifically for N3 head and neck cancer are lacking. This study aimed to compare the treatment outcomes between definitive concurrent chemoradiotherapy (CCRT) to the neck and upfront neck dissection followed by adjuvant CCRT. 93 N3 squamous cell carcinoma head and neck cancer patients were included. Primary tumor treatment was divided to definitive CCRT (CCRT group) or curative surgery followed by adjuvant CCRT (surgery group). Neck treatment was also classified into two treatment modalities: definitive CCRT to the neck (CCRT group) or curative neck dissection followed by adjuvant CCRT (neck dissection group). Overall, the 2-year overall survival (OS), local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), and distant metastasis-free survival (DMFS) were 51.8%, 47.3%, 45.6%, and 43.6%, respectively. In both oropharyngeal cancer and nonoropharyngeal cancer patients, in terms of OS, LRFS, RRFS or DMFS no difference was noted regarding primary tumor treatment (CCRT vs. surgery) or neck treatment (CCRT vs. neck dissection). In summary, N3 neck patients treated with definitive CCRT can achieve similar outcomes to those treated with upfront neck dissection followed by adjuvant CCRT. Cautions should be made to avoid overtreatment for this group of patients.

Download Full-text

Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines

The Journal of Laryngology & Otology ◽

10.1017/s0022215116000463 ◽

2016 ◽

Vol 130 (S2) ◽

pp. S66-S67 ◽

Cited By ~ 9

Author(s):

C Nutting

Keyword(s):

Head And Neck Cancer ◽

United Kingdom ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Treatment Modalities ◽

Current Role ◽

Cancer Management ◽

Recent Advances ◽

The Uk

AbstractThis is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Radiotherapy is one of the key treatment modalities used in head and neck cancer management. This paper summarises the current role and some of the recent advances in radiotherapy in head and neck cancer management.

Download Full-text

Prognostic evaluation in head and neck cancer patients: a clinicoimaging tertiary care center study

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20213778 ◽

2021 ◽

Vol 8 (10) ◽

pp. 4831

Author(s):

N. Kavya Keerthika ◽

D. Sri Veda ◽

M. P. V. Prabhat ◽

G. Sarat ◽

Gunmeet Maini

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Care Center ◽

Tertiary Care ◽

World Health ◽

Treatment Modalities ◽

Prognostic Evaluation ◽

Etiological Factors

Background: The occurrence of the head and neck cancers (HNC) is increasing day by day. These have been associated with multiple etiological factors, and early diagnosis has a prime role in the patient's prognosis and overall survival. Prognostic evaluation in head and neck cancer patients utilizing clinical incidence and imaging outcomes.Methods: The study sample included 217 confirmed HNC patients’ data obtained from the tertiary cancer care centre were analysed to assess the prognosis and be subjected to statistical analysis.Results: Out of all HNC, cancer pertaining to the lip and oral cavity was the most common variety with 65.89% and most of the HNC occurred in men of about 97%, suggesting a strong association with adverse oral habits.Conclusions: We conclude that the current scenario of HNC’s progression and treatment modalities in Andhra Pradesh were in comparison to the World Health Organization (WHO) data suggests an increase in the awareness of the etiological factors and the disease progression. Though various advanced imaging and treatment modalities are available, the patients' prognosis is untethered due to low socio-economic status in this region.

Download Full-text

Systemic Effects of Radiotherapy and Concurrent Chemo-Radiotherapy in Head and Neck Cancer Patients—Comparison of Serum Metabolome Profiles

Metabolites ◽

10.3390/metabo10020060 ◽

2020 ◽

Vol 10 (2) ◽

pp. 60 ◽

Cited By ~ 1

Author(s):

Karol Jelonek ◽

Aleksandra Krzywon ◽

Patrycja Jablonska ◽

Ewa M. Slominska ◽

Ryszard T. Smolenski ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Treatment Modalities ◽

Individual Response ◽

Serum Samples ◽

Molecular Changes ◽

Radiotherapy Alone ◽

The Individual

Anticancer treatment induces systemic molecular changes that could be detected at the level of biofluids. Understanding how human metabolism is influenced by these treatments is crucial to predict the individual response and adjust personalized therapies. Here, we aimed to compare profiles of metabolites in serum of head and neck cancer patients treated with concurrent chemo-radiotherapy, radiotherapy alone, or induction chemotherapy. Serum samples were analyzed by a targeted quantitative approach using combined direct flow injection and liquid chromatography coupled to tandem mass spectrometry, which allowed simultaneous quantification of 149 metabolites. There were 45 metabolites whose levels were significantly changed between pretreatment and within- or post-treatment serum samples, including 38 phospholipids. Concurrent chemo-radiotherapy induced faster and stronger effects than radiotherapy alone. On the other hand, chemotherapy alone did not result in significant changes. The decreased level of total phospholipids was the most apparent effect observed during the first step of the treatment. This corresponded to the loss of patients’ body mass, yet no correlation between both parameters was observed for individual patients. We concluded that different molecular changes were measured at the level of serum metabolome in response to different treatment modalities.

Download Full-text

1049 POSTER Photodynamic therapy and fluorescent diagnostics with different second-generation photosensitizers in head and neck cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81344-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 302-303

Keyword(s):

Head And Neck Cancer ◽

Photodynamic Therapy ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Second Generation

Download Full-text

Photodynamic Therapy for Head and Neck Cancer

Diagnostic and Therapeutic Endoscopy ◽

10.1155/dte.3.41 ◽

1996 ◽

Vol 3 (1) ◽

pp. 41-51 ◽

Cited By ~ 4

Author(s):

Tomoyuki Yoshida ◽

Harubumi Kato ◽

Tetsuya Okunaka ◽

Tetsuo Saeki ◽

Shinya Ohashi ◽

...

Keyword(s):

Head And Neck Cancer ◽

Photodynamic Therapy ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Adverse Reactions ◽

Pharyngeal Cancer ◽

Term Outcome ◽

Long Term Outcome

Photodynamic therapy (PDT) is a recently developed treatment involving the use of a photosensitizer and low power light, usually from a laser, to selectively destroy tumor cells. At present, we perform PDT for head and neck cancer using argon or excimer dye lasers with hematoporphyrin derivative as a photosensitizer. This study attempted to assess the utility and safety of PDT and to investigate the long-term outcome. All 24 patients had squamous cell carcinoma: 15 with laryngeal, 5 with lingual or oral, and 4 with pharyngeal cancer and were treated by PDT. Data were obtained from records from February 1988 through April 1995. After PDT, 12 of 15 laryngeal cancer patients were classified as having a complete remission (CR), as were 2 of the 5 lingual or oral and one of the 4 pharyngeal cancer patients. The patients were followed for 8 to 153 months. The longest duration of CR in patients treated by PDT alone was 148 months. Photosensitivity was experienced by all patients, but required no treatment. Liver, kidneys, and bone marrow showed no abnormal values. There were no clinically relevant adverse reactions, and patients with severe complications due to other types of treatment and elderly patients were also treated safely with this therapy.

Download Full-text

Chemo-Radiotherapeutic Management of Advanced Head and Neck Cancer

Tumori Journal ◽

10.1177/030089168907500618 ◽

1989 ◽

Vol 75 (6) ◽

pp. 600-604

Author(s):

Luigi Pirtoli ◽

Enrico Tucci ◽

Fiorella Pepi ◽

Lucio Sebaste ◽

Mirco Bindi ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Remission Rate ◽

Locally Advanced ◽

Complete Response ◽

Treatment Modalities ◽

Advanced Head ◽

Drug Administration Schedule

Stage III and IV head and neck cancer patients usually achieve poor therapeutic results after radiotherapy. The search for more effective treatment modalities is justified, provided that tolerance is not lower than that of the usual radiation therapy schedules. Chemotherapy has been shown to be effective, and cisplatinum and bleomycin based treatments are reported to result in objective remissions in a substantial proportion of cases. There is also experimental evidence of a radiosensitizing activity of cisplatinum. Thirty-five locally advanced head and neck cancer patients were given combined chemo-radiotherapeutic treatment consisting of a cisplatinum and bleomycin induction followed by a standard radiotherapy course integrated with weekly administrations of cisplatinum. Before radiotherapy, an overall 48.5 % objective remission rate was achieved, that rose to 85.8 % after completion of the entire treatment, with a 31.5 % complete response rate. Incidence and severity of radiation mucositis seem not to be increased, and systemic toxicity is very low, with the adopted drug administration schedule. Overall results do not show any obvious superiority over those of radiotherapy alone.

Download Full-text